Welcome to our dedicated page for Insight Molecular Diagnostics SEC filings (Ticker: IMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Insight Molecular Diagnostics Inc. (IMDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a California-incorporated public company listed on Nasdaq, Insight Molecular Diagnostics files current and periodic reports that describe its financial condition, governance decisions, and key developments in its precision diagnostics business.
Through forms such as 8-K, investors can review announcements related to executive compensation changes, stock option grants under the company’s equity incentive plan, amendments to employment agreements, and other material events. Earnings-related 8-K filings furnish press releases that summarize quarterly financial results and business updates, including progress on the GraftAssure dd-cfDNA transplant testing platform.
In addition to current reports, users can locate annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy materials that address governance matters and executive compensation. These filings provide context on how Insight Molecular Diagnostics manages its transplant-focused diagnostics programs, quality and regulatory activities, and broader corporate strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major topics without reading every page. Real-time updates from EDGAR ensure that new IMDX filings, including any future registration statements or insider transaction reports on Form 4, are added as they become available. This page is a central resource for analyzing the regulatory record of Insight Molecular Diagnostics and its dd-cfDNA-based diagnostics business.
Insight Molecular Diagnostics Inc. (iMDx) is asking shareholders to approve four items at its 2026 virtual annual meeting, including re-electing four directors, ratifying CBIZ CPAs as auditor, a non-binding say-on-pay vote, and a 1,750,000-share increase to its 2018 Equity Incentive Plan for a new total of 5,550,000 shares.
The proxy highlights iMDx’s strategy to decentralize transplant organ health monitoring through its dd-cfDNA assay platform. The company has submitted its GraftAssureDx test kit to the FDA for in vitro diagnostic marketing authorization and is running a 5,000-patient registry across 50 hospitals, supported by a partnership with Bio-Rad Laboratories, which owns just under 10% of iMDx.
As of the April 27, 2026 record date, iMDx had 32,288,039 common shares outstanding. The filing also details board independence, committee structures, a clawback policy, an insider trading policy that prohibits hedging, and 2024–2025 compensation and equity awards for directors and named executive officers.
Insight Molecular Diagnostics Inc. filed a current report to correct an exhibit previously attached to its Annual Report on Form 10-K for the year ended December 31, 2025. The earlier filing inadvertently included shareholder voting provisions that are not part of the Company’s Third Amended and Restated Bylaws.
The Company is now providing the correct copy of its Third Amended and Restated Bylaws as Exhibit 3.1 to this report. The correction is described as a clerical error and does not change any other disclosures contained in the Form 10-K.
Broadwood Partners, Broadwood Capital and Neal C. Bradsher report beneficial ownership of 12,835,134 Insight Molecular Diagnostics shares, representing 39.7% of the common stock. The amendment reflects an updated ownership percentage based on 32,318,071 shares outstanding, adjusted to include warrants they beneficially own.
Broadwood Partners and Broadwood Capital each report shared voting and dispositive power over 12,834,977 shares, while Mr. Bradsher also holds 157 shares with sole voting and dispositive power. The group funded its investment from working capital and personal funds, without dedicated borrowing beyond ordinary-course working capital.
The reporting persons state they will continue to review their investment and may discuss strategic alternatives with management, the board and other shareholders, and reserve the right to pursue various transactions or actions in compliance with securities laws.
Insight Molecular Diagnostics Inc. insider Broadwood Partners, L.P., together with related entities, reported net open-market purchases of 570,184 shares of IMDX common stock. The buys occurred between April 23 and April 27 in multiple tranches at weighted average prices around $3.50–$3.64 per share.
After these transactions, entities associated with Neal C. Bradsher report holding 12,684,884 shares of common stock, plus warrants currently exercisable for a total of 300,186 additional shares at an exercise price of $30.60 per share that expire on April 19, 2027.
Insight Molecular Diagnostics Inc. shareholder entities associated with Broadwood Partners, L.P. and Neal C. Bradsher reported open-market purchases of 182,861 shares of common stock. The shares were bought between April 16 and April 20 at weighted average prices of $3.4457, $3.5711, and $3.8822 per share, across specified price ranges disclosed in the footnotes.
Following these transactions, Broadwood Partners is shown with 12,114,700 indirectly owned Insight Molecular common shares, while Neal C. Bradsher directly owns a small additional common stock position. The filing also lists currently exercisable warrants, held both directly and indirectly, each for 150,093 underlying shares at an exercise price of $30.60 per share expiring on April 19, 2027.
Insight Molecular Diagnostics Inc. Chief Financial Officer James Andrea reported routine equity compensation activity. On March 26, 2026, 28,302 Restricted Stock Units (RSUs) vested into an equal number of common shares under the company’s 2018 Equity Incentive Plan.
The company withheld 11,298 common shares at $4.11 per share to cover required tax obligations, and the filing states that the reporting person did not sell any shares. After these transactions, he directly holds 206,060 common shares and 84,905 RSUs. The RSU award vests over four years, with 25% vesting on March 26, 2026 and the remaining 75% vesting in equal annual installments, subject to continued service.
Insight Molecular Diagnostics Inc. reported that VP, Controller and Treasurer Liu James Yang had restricted stock units vest into 6,289 shares of common stock on March 26, 2026 under the 2018 Equity Incentive Plan. The company withheld 2,578 shares at $4.11 per share to cover tax obligations, and no shares were sold. After these transactions, Yang directly holds 3,711 shares of common stock and 12,578 restricted stock units, with the remaining units scheduled to vest over the next two years, subject to continued service.
Insight Molecular Diagnostics CEO Josh Riggs reported a compensation-related stock transaction involving restricted stock units (RSUs). On March 26, 2026, 47,170 RSUs vested and were converted into the same number of common shares at an exercise price of $0.00 per share under the company’s 2018 Equity Incentive Plan.
To cover required tax withholding on this vesting, 12,310 common shares were withheld by the company at $4.11 per share. The filing states that Riggs did not sell any shares; the disposition was solely for tax obligations. Following these transactions, he directly held 38,365 common shares, and the remaining 75% of the original RSU award is scheduled to vest in equal installments over the next three years, subject to continuous service.
Insight Molecular Diagnostics Inc. is a diagnostics technology company focused on molecular tests for transplanted organ rejection, supported by an intellectual property portfolio in transplant and oncology. Its flagship GraftAssure family measures donor-derived cell-free DNA, offered as a CLIA-lab test and kitted products developed with Bio-Rad.
In 2025 the company began a clinical trial for its GraftAssureDx in vitro diagnostic kit and submitted a data package to the FDA on March 25, 2026, initially targeting kidney transplants. CMS provides coverage for GraftAssureCore and increased reimbursement to $2,753 per result.
The 10-K highlights continued operating losses, with a net loss of $50.2 million in 2025 and an accumulated deficit of $400.8 million, and notes reliance on external financing until test revenues can cover expenses. Key risks include limited near-term revenue concentration in a few tests, intense competition, reimbursement uncertainty, extensive regulatory requirements in the U.S. and abroad, and the need to protect and enforce patents and trade secrets. The company had 58 employees as of December 31, 2025.